pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
BRISTOL · news · pharmadog
← back to BRISTOL
News mentioning BRISTOL
236
stories
27d
AstraZeneca scores in lung cancer; Sandoz inks a China deal
biopharma dive
27d
Merck and Sarah Cannon team up to boost oncology trial efficiency
fiercebiotech
27d
STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more
stat
27d
STAT+: Amylyx endocrine drug succeeds in pivotal study
stat
27d
STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
stat
28d
STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise
stat
28d
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
28d
STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit
stat
28d
STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more
stat
28d
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
fiercebiotech
Aug 14, 26
Cytokinetics brings patent suit against Bristol Myers, escalating rivalry
endpoints
Aug 14, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
Aug 14, 26
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
biopharma dive
Aug 14, 26
STAT+: PBMs agree to display TrumpRx drug prices
stat
Aug 14, 26
STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more
stat
Aug 14, 26
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
Aug 14, 26
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
stat
Aug 14, 26
BMS welcomes new multiple myeloma drug as generics batter current portfolio
biospace
Aug 14, 26
MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter
fiercebiotech
Aug 13, 26
FDA approves Bristol Myers' multiple myeloma successor
endpoints
Aug 12, 26
With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
biospace
Aug 11, 26
AbbVie, Novartis and Bristol Myers file 340B lawsuits in Illinois
endpoints
Aug 10, 26
Bristol Myers details new $2.3B manufacturing campus in Houston
endpoints
Aug 10, 26
BMS picks Texas for new $2.3B manufacturing campus
biospace
Aug 10, 26
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
fiercebiotech
Aug 10, 26
As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
biospace
Aug 10, 26
Recon: BMS plans $2.3B Houston manufacturing site; MHRA approves Lilly weight-loss drug for weight loss, type 2 diabetes
raps
Aug 7, 26
Why Big Pharma is chasing the industry’s most-powerful supercomputer
biopharma dive
Aug 6, 26
Replimune rebounds to win FDA approval of melanoma drug
biopharma dive
Aug 6, 26
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
biospace
← prev
page 3 of 8
next →
